Abstract
Abstract:A 50-year-old woman was referred to our emergency room because of urticaria. Eleven days after etanercept therapy was started, the patient developed an urticarial rash of the trunk and face. A diagnosis of generalized urticaria was made. Etanercept treatment was suspended. Treatment was started with methylprednisolone and dexchlorpheniramine. The patient’s condition improved and she was discharged. In this case, the most probable cause of urticaria was considered to be etanercept because of the temporal relationship between exposure to the drug and the onset of symptoms. The adverse reaction could be considered probable. Although the overall risk of skin adverse events associated with etanercept appears low, clinicians should be aware of this reaction.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Fuchs BS, Hadi S. Use of etanercept in the treatment of psoriasis and psoriatic arthritis. Rev Recent Clin Trials 2006;1:259–263.FuchsBS]]HadiSUse of etanercept in the treatment of psoriasis and psoriatic arthritis.Rev Recent Clin Trials20061259-2632. Johnson CJ, Reilly KM, Murray KM. Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother 2001;35:464–471.JohnsonCJ]]ReillyKM]]MurrayKMEtanercept in juvenile rheumatoid arthritis.Ann Pharmacother200135464-4713. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478–486.MorelandLW]]SchiffMH]]BaumgartnerSW&etal;Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.Ann Intern Med1999130478-4864. Quintos-Macasa AM, Quinet R. Enbrel-induced interstitial lung disease. South Med J 2006;99:783–784.Quintos-MacasaAM]]QuinetREnbrel-induced interstitial lung disease.South Med J200699783-7845. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–2291.GarrettS]]JenkinsonT]]KennedyLG&etal;A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.J Rheumatol1994212286-22916. Gómez-Reino JJ, Carmona L, Valverde VR, et al; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122–2127.Gómez-ReinoJJ]]CarmonaL]]ValverdeVR&etal;BIOBADASER GroupTreatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.Arthritis Rheum2003482122-21277. Bovenschen HJ, Kop EN, Van De Kerkhof PC, et al. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatolog Treat 2006;17:381–383.BovenschenHJ]]KopEN]]Van De KerkhofPC&etal;Etanercept-induced lichenoid reaction pattern in psoriasis.J Dermatolog Treat200617381-3838. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041–2044.GalariaNA]]WerthVP]]SchumacherHRLeukocytoclastic vasculitis due to etanercept.J Rheumatol2000272041-20449. Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 2002;61:850–851.SoliotisF]]GloverM]]JawadASSevere skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis.Ann Rheum Dis200261850-85110. United States Food and Drug Administration. Tumor necrosis factor alpha (TNF-a) antagonists [infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and adalimumab (marketed as HUMIRA)]: serious skin reactions. FDA Drug Saf Newslett 2008;1:18–22.United States Food and Drug AdministrationTumor necrosis factor alpha (TNF-a) antagonists [infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and adalimumab (marketed as HUMIRA)]: serious skin reactions.FDA Drug Saf Newslett2008118-2211. Skyttä E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000;18:533–534.SkyttäE]]PohjankoskiH]]SavolainenAEtanercept and urticaria in patients with juvenile idiopathic arthritis.Clin Exp Rheumatol200018533-53412. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.NaranjoCA]]BustoU]]SellersEM&etal;A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther198130239-245
